The prognostic value of phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha(PIK3CA) in patients with esophageal squamous cell carcinoma(ESCC) is controversial. We aimed to investigate the prognost...The prognostic value of phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha(PIK3CA) in patients with esophageal squamous cell carcinoma(ESCC) is controversial. We aimed to investigate the prognostic significance of PIK3CA mutation in patients with ESCC. EMBASE, Pub Med, and Web of Science databases were systematically searched from inception through Oct. 3, 2016. The hazard ratios(HRs) and 95% confidence intervals(CI) were calculated using a random effects model for overall survival(OS) and disease-free survival(DFS). Seven studies enrolling 1505 patients were eligible for inclusion of the current meta-analysis. Results revealed that PIK3CA mutation was not significantly associated with OS(HR: 0.90, 95% CI: 0.63–1.30, P=0.591), with a significant heterogeneity(I2=65.7%, P=0.012). Additionally, subgroup analyses were further conducted according to various variables, such as types of specimen, the sample size, technique and statistical methodology. All results suggested that no significant relationship was found between PIK3CA mutation and OS in patients with ESCC. For DFS, there was no significant association between PIK3CA mutation and DFS in patients with ESCC(HR: 1.00, 95% CI=0.47–2.11, P=0.993, I2=73.7%). Publication bias was not present and the results of sensitivity analysis were very stable in the current meta-analysis. Our findings suggest that PIK3CA mutation has no significant effects on OS and DFS in ESCC patients. More well-designed prospective studies with better methodology for PIK3CA assessment are required to clarify the prognostic significance of PIK3CA mutation in ESCC patients.展开更多
目的:探讨与分析高通量测序平台研究非小细胞肺癌热点基因突变情况。方法:选择2019年11月-2020年11月在本院肿瘤科诊治的非小细胞肺癌患者110例作为肺癌组,同期选择健康体检者110例作为对照组,提取血浆组织,采用高通量测序平台分析基因...目的:探讨与分析高通量测序平台研究非小细胞肺癌热点基因突变情况。方法:选择2019年11月-2020年11月在本院肿瘤科诊治的非小细胞肺癌患者110例作为肺癌组,同期选择健康体检者110例作为对照组,提取血浆组织,采用高通量测序平台分析基因表达差异情况,重点检测热点基因突变情况。结果:两组所有入选者DNA提取体积>40μl,浓度>1ng/μl,总量>55ng,<200nt比例<5%,都符合质控要求,两组对比差异无统计学意义(P>0.05)。两组筛选出显著差异表达的基因共1245个,其中肺癌组表达上调652个,表达下调593个。基因测序与实时荧光定量PCR显示肺癌组的鼠肉瘤病毒致癌基因(Kirsten rat sarcoma viral oncogene,KRAS)、磷脂酰肌醇-3-激酶催化亚基α基因(Phosphoinositide-3-kinase,catalytic,alpha gene,PIK3CA)、肿瘤蛋白P53(Tumor protein P53,TP53)表达水平都高于对照组(P<0.05)。基因测序显示肺癌组的KRAS、PIK3CA、TP53基因突变率分别为30.0%、22.7%、17.3%,高于对照组的3.6%、1.8%和0.9%(P<0.05)。结论:高通量测序平台能有效检出非小细胞肺癌热点基因突变情况,具有很好的应用可行性,值得推广应用。展开更多
文摘The prognostic value of phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha(PIK3CA) in patients with esophageal squamous cell carcinoma(ESCC) is controversial. We aimed to investigate the prognostic significance of PIK3CA mutation in patients with ESCC. EMBASE, Pub Med, and Web of Science databases were systematically searched from inception through Oct. 3, 2016. The hazard ratios(HRs) and 95% confidence intervals(CI) were calculated using a random effects model for overall survival(OS) and disease-free survival(DFS). Seven studies enrolling 1505 patients were eligible for inclusion of the current meta-analysis. Results revealed that PIK3CA mutation was not significantly associated with OS(HR: 0.90, 95% CI: 0.63–1.30, P=0.591), with a significant heterogeneity(I2=65.7%, P=0.012). Additionally, subgroup analyses were further conducted according to various variables, such as types of specimen, the sample size, technique and statistical methodology. All results suggested that no significant relationship was found between PIK3CA mutation and OS in patients with ESCC. For DFS, there was no significant association between PIK3CA mutation and DFS in patients with ESCC(HR: 1.00, 95% CI=0.47–2.11, P=0.993, I2=73.7%). Publication bias was not present and the results of sensitivity analysis were very stable in the current meta-analysis. Our findings suggest that PIK3CA mutation has no significant effects on OS and DFS in ESCC patients. More well-designed prospective studies with better methodology for PIK3CA assessment are required to clarify the prognostic significance of PIK3CA mutation in ESCC patients.
文摘目的:探讨与分析高通量测序平台研究非小细胞肺癌热点基因突变情况。方法:选择2019年11月-2020年11月在本院肿瘤科诊治的非小细胞肺癌患者110例作为肺癌组,同期选择健康体检者110例作为对照组,提取血浆组织,采用高通量测序平台分析基因表达差异情况,重点检测热点基因突变情况。结果:两组所有入选者DNA提取体积>40μl,浓度>1ng/μl,总量>55ng,<200nt比例<5%,都符合质控要求,两组对比差异无统计学意义(P>0.05)。两组筛选出显著差异表达的基因共1245个,其中肺癌组表达上调652个,表达下调593个。基因测序与实时荧光定量PCR显示肺癌组的鼠肉瘤病毒致癌基因(Kirsten rat sarcoma viral oncogene,KRAS)、磷脂酰肌醇-3-激酶催化亚基α基因(Phosphoinositide-3-kinase,catalytic,alpha gene,PIK3CA)、肿瘤蛋白P53(Tumor protein P53,TP53)表达水平都高于对照组(P<0.05)。基因测序显示肺癌组的KRAS、PIK3CA、TP53基因突变率分别为30.0%、22.7%、17.3%,高于对照组的3.6%、1.8%和0.9%(P<0.05)。结论:高通量测序平台能有效检出非小细胞肺癌热点基因突变情况,具有很好的应用可行性,值得推广应用。
